Education
About Us
Working with TipRanks
Follow Us
Galera Therapeutics (GRTX)
OTHER OTC:GRTX
GRTX Stock Chart & Stats
$0.02
<$0.01(0.99%)
At close: 4:00 PM EST
$0.02
<$0.01(0.99%)
Day’s Range― - ―
52-Week Range$0.02 - $0.06
Previous CloseN/A
Volume48.38K
Average Volume (3M)63.57K
Market Cap
$3.41M
Enterprise Value-$2.98M
Total Cash (Recent Filing)$6.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)<0.1
Beta0.73
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding75,462,390
10 Day Avg. Volume87,114
30 Day Avg. Volume63,573
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.55
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet DeleveragingElimination of reported debt and a shift to small positive equity materially lowers near-term solvency risk and reduces refinancing pressure. This durable repair to capitalization improves flexibility for 2–6 months+ planning, making incremental financing or program funding less urgent.
Capital-structure FlexibilityBoard discretion to convert Series B preferred shares creates a structural tool to simplify capital structure and enable quicker strategic financing or share-class consolidation. That flexibility can reduce stakeholder conflict and facilitate durable execution of financing or M&A strategies.
Retention Of Key Financial OfficerSecuring the chief accounting officer supports continuity and reliable financial reporting during critical periods. Stable financial leadership reduces operational and regulatory risk around filings and financing activities, strengthening governance over the medium term.
Bears Say
Pre-revenue OperationsA multi-year pre-revenue profile with persistently negative operating results means the company must rely on external capital to fund R&D and operations. This structural dependence increases dilution and execution risk for clinical programs over the next several quarters.
Poor Cash GenerationSustained negative operating and free cash flows indicate the company is not self-funding and remains vulnerable to funding gaps. Absent durable positive cash generation, management will need fresh capital for operations and trials, making long-term program continuity contingent on financing.
Thin Capital Base And Small ScaleA small asset/equity base and a three-person workforce constrain internal execution capacity and absorbable shocks. Limited scale raises reliance on outsourcing and partners, increasing execution and operational risk for clinical development over a multi-month horizon.
Galera Therapeutics News
GRTX FAQ
What was Galera Therapeutics’s price range in the past 12 months?
Galera Therapeutics lowest stock price was $0.01 and its highest was $0.06 in the past 12 months.
What is Galera Therapeutics’s market cap?
Galera Therapeutics’s market cap is $3.41M.
When is Galera Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Galera Therapeutics’s earnings last quarter?
Currently, no data Available
Is Galera Therapeutics overvalued?
According to Wall Street analysts Galera Therapeutics’s price is currently Overvalued.
Does Galera Therapeutics pay dividends?
Galera Therapeutics does not currently pay dividends.
What is Galera Therapeutics’s EPS estimate?
Galera Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galera Therapeutics have?
Galera Therapeutics has 75,462,390 shares outstanding.
What happened to Galera Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Galera Therapeutics?
Currently, no hedge funds are holding shares in GRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galera Therapeutics
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Technical Analysis
Ownership Overview
10.40% Insiders
<0.01% Mutual Funds
3.90% Other Institutional Investors
85.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---